Drug intelligence / Profile preview

clostridium caseinate + enterococcus triad

Development stage
Unknown
Lead developer
Miyarisan Pharmaceutical
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

This is a combination product containing strains or preparations of Clostridium (likely as "clostridium caseinate," though this term is not standard and may refer to a preparation involving Clostridium species, possibly Clostridium butyricum or related) and Enterococcus (as "enterococcus triad," which likely refers to a mixture of three Enterococcus strains, commonly including Enterococcus faecium). Such combinations are typically used as probiotics intended to modulate the gut microbiota, support intestinal health, and potentially prevent or treat gastrointestinal disorders. The mechanism of action involves competitive inhibition of pathogenic bacteria, modulation of immune responses in the gut mucosa, enhancement of mucosal barrier function, and production of beneficial metabolites such as short-chain fatty acids. There is evidence that both C. butyricum and E. faecium can alter the structure of the gut microbiota; however, studies have not consistently shown synergistic effects when combined[4][5]. These products are generally considered safe for use in animals and humans for dietary supplementation.

Beyond the preview

Go deeper on clostridium caseinate + enterococcus triad.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clostridium caseinate + enterococcus triad.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call